tarenflurbil has been researched along with flurbiprofen in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 16 (66.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bigogno, C; Biscaioli, M; Bolzoni, PT; Caruso, P; Catinella, S; Cenacchi, V; Del Giudice, E; Dondio, G; Facchinetti, F; Fontanella, L; Imbimbo, BP; Marchetti, S; Misiano, P; Moretto, N; Parini, C; Peretto, I; Puccini, P; Radaelli, S; Raveglia, LF; Riccardi, B; Rizzi, A; Rondelli, I; Villetti, G; Zandi, M | 1 |
| Berthelot, DJ; Gijsen, HJ; Oehlrich, D | 1 |
| Hendrix, SB; Wilcock, GK | 1 |
| Imbimbo, BP | 1 |
| Amato, DA; Beelen, AP; Green, RC; Schneider, LS; Swabb, EA; Wilcock, G; Zavitz, KH | 1 |
| Larson, EB; Montine, TJ | 1 |
| Vellas, B | 1 |
| Feuerstein, GZ; Jacobsen, JS; Rutkowski, JL; Wan, HI | 1 |
| Matsuoka, N; Mitani, Y; Miyake, A; Nagakura, A; Shitaka, Y | 1 |
| Shoji, M | 1 |
| Holtzman, JL | 1 |
| Frisardi, V; Greco, A; Imbimbo, BP; Logroscino, G; Panza, F; Pilotto, A; Santamato, A; Seripa, D; Solfrizzi, V | 1 |
| Hanlon, E; Morin, P; Wong, ST; Xia, W | 1 |
| Iwai, A | 1 |
| Alva, G; Hara, J; Hendrix, S; Lee, MD; Mangrola, T; Shankle, WR | 1 |
| Asakura, K; Evans, SR; Hamasaki, T; Hayashi, K; Sozu, T; Sugimoto, T | 1 |
| Gong, T; Li, Y; Shuai, X; Sun, X; Zhang, Z; Zheng, D; Zhou, P | 1 |
| Dubský, P; Gaš, B; Müllerová, L | 1 |
| Challa, VG; Dhommati, R; Jain, A; Khan, W; Muntimadugu, E; Shaheen, M | 1 |
| Ho, PC; Wong, LR | 1 |
| Ashtikar, M; Geisslinger, G; Jung, F; Nothnagel, L; Parnham, MJ; Rossmanith, T; Thurn, M; Wacker, MG | 1 |
| Ge, S; Guyatt, G; Lu, L; Tang, C; Wang, S; Wen, H; Xu, M; Xu, N; Yao, G; Zeng, J; Zhang, Y; Zheng, X | 1 |
| Alig, E; Dressman, J; Fink, L; Jung, F; Krollik, K; Li, D; Schmidt, MU; Thurn, M; Wacker, MG | 1 |
7 review(s) available for tarenflurbil and flurbiprofen
| Article | Year |
|---|---|
γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cinnamates; Clinical Trials as Topic; Ginsenosides; Humans; Isoenzymes; Stereoisomerism | 2011 |
[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Azepines; Drug Design; Enzyme Inhibitors; Flurbiprofen; Humans; Taurine | 2010 |
[Drug therapy for Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Clioquinol; Drug Design; Excitatory Amino Acid Antagonists; Flurbiprofen; Indoles; Memantine; Meta-Analysis as Topic; Randomized Controlled Trials as Topic | 2010 |
Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Azepines; Enzyme Inhibitors; Flurbiprofen; Humans | 2011 |
γ-Secretase modulator in Alzheimer's disease: shifting the end.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Azepines; Clinical Trials as Topic; Flurbiprofen; Humans | 2012 |
[Gamma-secretase inhibitors and modulators].
Topics: Alanine; Alzheimer Disease; Amyloid Precursor Protein Secretases; Azepines; Flurbiprofen; Humans | 2011 |
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Topics: Acitretin; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Anxiety; Azepines; Clioquinol; Copper; Cyclic S-Oxides; Depression; Diarrhea; Exanthema; Fatigue; Flurbiprofen; Humans; Immunoglobulins, Intravenous; Inositol; Mental Status and Dementia Tests; Minimal Clinically Important Difference; Orotic Acid; Oxadiazoles; Severity of Illness Index; Sulfonamides; Syncope; Thiadiazines; Treatment Outcome; Vomiting | 2020 |
1 trial(s) available for tarenflurbil and flurbiprofen
| Article | Year |
|---|---|
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Cognition; Cognition Disorders; Double-Blind Method; Enzyme Inhibitors; Female; Flurbiprofen; Humans; Male; Middle Aged; Peptide Fragments | 2009 |
16 other study(ies) available for tarenflurbil and flurbiprofen
| Article | Year |
|---|---|
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Caco-2 Cells; Cell Line, Tumor; Cell Membrane Permeability; Cyclooxygenase Inhibitors; Flurbiprofen; Glioma; Humans; Immunoassay; In Vitro Techniques; Injections, Intravenous; Mice; Mice, Transgenic; Peptide Fragments; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stereoisomerism; Structure-Activity Relationship | 2005 |
What we have learned from the Myriad trials.
Topics: Alzheimer Disease; Flurbiprofen; Humans; Randomized Controlled Trials as Topic; Research Design | 2009 |
Why did tarenflurbil fail in Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Brain; Flurbiprofen; Humans; Treatment Failure | 2009 |
Late-life dementias: does this unyielding global challenge require a broader view?
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Comorbidity; Cost of Illness; Dementia; Enzyme Inhibitors; Flurbiprofen; Global Health; Humans; Leptin; Longevity; Peptide Fragments | 2009 |
Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase III as Topic; Flurbiprofen; Goals; Humans | 2010 |
Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
Topics: Alzheimer Disease; Animals; Biomarkers; Clinical Trials as Topic; Disease Progression; Drug Discovery; Flurbiprofen; Humans; Patient Selection; Reproducibility of Results; Translational Research, Biomedical; Treatment Failure | 2009 |
Disease-modifying drug fails in Alzheimer's study.
Topics: Activities of Daily Living; Alzheimer Disease; Amyloid Precursor Protein Secretases; Cognition; Cognition Disorders; Flurbiprofen; Humans; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome | 2010 |
Are we prepared to deal with the Alzheimer's disease pandemic?
Topics: Aging; Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Animals; Disease Outbreaks; Flurbiprofen; Humans; Mice; Mice, Transgenic; Presenilin-1; United States | 2010 |
Hierarchical Bayesian cognitive processing models to analyze clinical trial data.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Amyloid Precursor Protein Secretases; Bayes Theorem; Clinical Trials, Phase III as Topic; Cognitive Dysfunction; Disease Progression; Double-Blind Method; Female; Flurbiprofen; Humans; Male; Mental Recall; Models, Psychological; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuropsychological Tests; Nootropic Agents; Normal Distribution; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index | 2013 |
Sample size determination in group-sequential clinical trials with two co-primary endpoints.
Topics: Activities of Daily Living; Alzheimer Disease; Clinical Trials as Topic; Cognition; Flurbiprofen; Humans; Models, Statistical; Research Design; Sample Size; Treatment Outcome | 2014 |
Novel flurbiprofen derivatives with improved brain delivery: synthesis, in vitro and in vivo evaluations.
Topics: Animals; Brain; Cell Line; Deanol; Drug Carriers; Endothelial Cells; Flurbiprofen; Male; Mice; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2016 |
Generalized model of electromigration with 1:1 (analyte:selector) complexation stoichiometry: part II. Application to dual systems and experimental verification.
Topics: beta-Cyclodextrins; Electrophoresis, Capillary; Flurbiprofen; Hydrogen-Ion Concentration; Models, Theoretical; Stereoisomerism | 2015 |
Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Brain; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Stability; Flurbiprofen; Lactic Acid; Lipids; Liver; Lung; Male; Myocardium; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Sprague-Dawley; Spleen | 2016 |
Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease.
Topics: Administration, Intranasal; Administration, Oral; Alzheimer Disease; Animals; Brain; CHO Cells; Cricetulus; Drug Carriers; Drug Delivery Systems; Flurbiprofen; Male; Mice; Mice, Inbred C57BL; Mitochondria; Nanoparticles; Neuroprotective Agents; Serum Albumin; Tissue Distribution | 2018 |
Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001.
Topics: Administration, Oral; Anti-Inflammatory Agents; Computer Simulation; Deglutition; Deglutition Disorders; Drug Compounding; Drug Liberation; Flurbiprofen; Gastric Emptying; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Multiple Sclerosis; Solubility; Suspensions | 2019 |
Sustained-release hot melt extrudates of the weak acid TMP-001: A case study using PBB modelling.
Topics: Administration, Oral; Arginine; Biological Availability; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Drug Stability; Excipients; Flurbiprofen; Humans; Models, Biological; Multiple Sclerosis; Polymethacrylic Acids; Solubility; X-Ray Diffraction | 2021 |